Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | CNR1 | P21554 | 3/20 | 0.48 |
| ▸ | CNR2 | P34972 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 3/20 | 0.45 |
| ▸ | GSK3A | P49840 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ELANE | P08246 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2745695 | 0.85 | CNR1 (0.56) | KMT2AMEN1CNR1CNR2ALDH1A1 | |
| SCHEMBL10268766 | 0.85 | ALDH1A1 (0.48) | KMT2AMEN1CNR1CNR2ALDH1A1 | |
| SCHEMBL5542217 | 0.81 | CNR2 (0.64) | CNR1CNR2BRD4NOTUM | |
| SCHEMBL2746507 | 0.81 | TSHR (0.60) | KMT2AMEN1CNR1CNR2ALDH1A1 | |
| SCHEMBL5512991 | 0.78 | CNR2 (0.57) | CNR1CNR2ALDH1A1BRD4NOTUM | |
| SCHEMBL5510356 | 0.74 | CNR2 (0.52) | KMT2AMEN1CNR1CNR2ALDH1A1 | |
| SCHEMBL31560452 | 0.74 | ALDH1A1 (0.57) | KMT2AMEN1CNR1ALDH1A1ATM | |
| SCHEMBL29200758 | 0.73 | HPGD (0.60) | KMT2AMEN1CNR1CNR2ALDH1A1 | |
| SCHEMBL30783420 | 0.73 | HPGD (0.60) | KMT2AMEN1CNR1CNR2ALDH1A1 | |
| SCHEMBL2745641 | 0.73 | CNR2 (0.64) | CNR1CNR2ALDH1A1NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178681-B2 | methyl 3-methyl-2-{[2-oxo-1-(2-oxo-ethyl)-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-butyrate; cannabinoid receptor agonist; antiinflammatory agent, immunostimulant, analgesic; atopic dermatitis; excellent in photostability, and have excellent transdermal and oral absorbency | SHIONOGI & CO., LTD. (JP) | 2012-05-15 | — | — | US | disclosed |
| US-20080103139-A1 | 3-Carbamoyl-2-Pyridone Derivative | SHIONOGI & CO. LTD. (JP) | 2008-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103139-A1 | 3-Carbamoyl-2-Pyridone Derivative | CNR1, CNR2, HRH4 | KMT2A 2206/4885MEN1 3984/4885CNR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.